HCG Healthcare Global Enterprises Q3 FY26 results (Oct–Dec 2025) and concall
HealthCare Global reported a strong Q3 FY26 with 13.4% YoY revenue growth and 20% YoY adjusted EBITDA growth, driven by robust patient volumes and margin expansion. The company's digital strategy is yielding significant results, and regional clusters are performing well despite some temporary disruptions. HCG remains focused on leveraging existing capacity, brownfield expansion, and calibrated greenfield additions to achieve its long-term growth and margin targets, supported by a planned equity infusion.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 13.2%, net profit down 200.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 554 | 559 | 585 | 613 | 647 +17% | 633 +13% |
| EBITDA | 102 | 88 | 106 | 108 | 123 +21% | 110 +25% |
| Net profit | 21 | 8 | 7 | 6 | 21 +0% | -8 −200% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
